A large number of mouse monoclonal antibodies have been applied to cancer, infectious diseases and thrombosis for therapeutic purposes. However, their therapeuticeutic effects in human patients are limited, due to their high immunogenicity in humanp atients. To eliminate this immunogenicity, the humanization of mouse antibodies has been established using genetic engineering technology.
KeywordsSensor Chip Dissociation Rate Constant Chimeric Antibody Association Rate Constant Hepes Buffer Saline
Unable to display preview. Download preview PDF.
- 4.Sato K, Yamakawa Y, Shizume K, Satoh T, Nohtomi K, Demura H, Akatsu T, Nagata N, Kasahara T, Ohkawa H, Ohsumi K (1993) Passive Immunization with Anti-Parathyroid Hormone-Related Protein Monoclonal Antibody Markedly Prolongs Survival Time of Hypercalcemic Nude Mice Bearing Transplanted Human PTHrP-Producing Tumors. J. Bone Mineral Res. 8: 849–860CrossRefGoogle Scholar
- 5.Onuma E, Sato K, Kaiho S, Miura M, Takahashi S, Ogata E (1999) The role of PTHrP in malignancy-associated hypercalcemia and cachexia. Cancer-Induced Bone Diseases, Second International Conference, Abstract 23Google Scholar
- 1.Wolfgang L G, Csernokt E, Helmchen U (1995) Antineutrophil cytoplasmic autoantibodies, autoantigens and systemic vasculitis. Acta Pathol. Microbiol. Scandanavica 103: 81–97Google Scholar
- 3.Laricchia-Robbio L, Liedberg B, Platou-Vikinge T, Rovero P, Beffy P, Revoltella R P (1996) Mapping of monoclonal antibody and receptor binding domains on human granulocyte-macrophage colony stimulating factor (rhGM-CSF) using a surface plasmon resonance based biosensor. Hybridoma 15: 343–350PubMedCrossRefGoogle Scholar